Kaneko T, Abe F, Ito M, Hotchi M, Yamada K, Okada Y
Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan.
Acta Pathol Jpn. 1991 Jul;41(7):561-6. doi: 10.1111/j.1440-1827.1991.tb02521.x.
A case of fatal intestinal mucormycosis in a 57-year-old female hemodialysis patient who had received desferrioxamine (DFO) for aluminum overload is reported. The focus of fungal infection was not found until the intestine had been resected surgically. DFO is being used with increased frequency in dialysis patients to treat aluminum or iron overload. Recently a possible link between DFO therapy and mucormycosis has been suggested. In the management of hemodialysis patients, the potential risk of mucormycosis with DFO therapy should be considered.
报道了一例57岁接受血液透析的女性患者，因铝过载接受去铁胺（DFO）治疗后发生致命性肠道毛霉菌病。直到手术切除肠道后才发现真菌感染灶。在透析患者中，DFO用于治疗铝或铁过载的频率越来越高。最近有人提出DFO治疗与毛霉菌病之间可能存在联系。在血液透析患者的管理中，应考虑DFO治疗导致毛霉菌病的潜在风险。
